Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

NCT06963346 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

12

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Bladder Cancer

Interventions

DRUG: Romidepsin
DRUG: Durvalumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]